drugset / Trial / NCT02526953
Efficacy Study of Chemoradiotherapy With or Without Paclitaxel in Squamous-cell Anal Carcinoma Patients
RandomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to determine whether the combination of paclitaxel, capecitabine, mitomycin and intensity-modulated radiotherapy is more effective than the standard combination of capecitabine, mitomycin and intensity-modulated radiotherapy (IMRT) in patients with squamous-cell anal cancer.
Timeline
- Start
- 2016-01
- Primary completion
- 2021-10
- Completion
- 2022-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Capecitabine | Small molecule | 625 mg/m2 | Oral |
| Comparator | Capecitabine | Small molecule | 825 mg/m2 | Oral |
| Comparator | Mitomycin C | Other / unclassified | 10 mg/m2 | Intravenous |
| Comparator | Mitomycin C | Other / unclassified | 12 mg/m2 | Intravenous |
| Subject | Paclitaxel | Small molecule | 45 mg/m2 | Intravenous |